Page 19 - Read Online

Gmeiner. Cancer Drug Resist 2019;2:994-1001 I http://dx.doi.org/10.20517/cdr.2019.95 Page 1001

Biochemistry 2002;41:839-46.
38. Gmeiner WH. Antimetabolite incorporation into DNA: structural and thermodynamic basis for anticancer activity. Biopolymers
2002;65:180-9.
39. Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, et al. Gemcitabine (2’,2’-difluoro-2’-deoxycytidine), an antimetabolite
that poisons topoisomerase I. Clin Cancer Res 2002;8:2499-504.
40. An Q, Robins P, Lindahl T, Barnes DE. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug
cytotoxicity. Cancer Res 2007;67:940-5.
41. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of
5-fluoro-2’-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38:3784-92.
42. Gmeiner WH. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 2005;12:191-202.
43. Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. Dihydropyrimidine dehydrogenase deficiency (Dpd) in Gi malignancies:
experience of 4-years. Pak J Med Sci 2007;23:832-9.
44. Dominijanni A, Gmeiner WH. Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations. Cancer
Drug Resist 2018;1:48-58.
45. Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS. The applications of the novel polymeric fluoropyrimidine F10 in cancer
treatment: current evidence. Future Oncol 2016;12:2009-20.
46. Liao ZY, Sordet O, Zhang HL, Kohlhagen G, Antony S, et al. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless
death with topoisomerase I-DNA complexes. Cancer Res 2005;65:4844-51.
47. Gmeiner WH, Reinhold WC, Pommier Y. Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison
of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther 2010;9:3105-14.
48. Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH. The poison oligonucleotide F10 is highly effective against acute
lymphoblastic leukemia while sparing normal hematopoietic cells. Oncotarget 2014;5:4170-9.
49. Holbeck SL, Collins JM, Doroshow JH. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of
human tumor cell lines. Mol Cancer Ther 2010;9:1451-60.
50. Gmeiner WH, Yu S, Pon RT, Pourquier P, Pommier Y. Structural basis for topoisomerase I inhibition by nucleoside analogs. Nucleosides
Nucleotides Nucleic Acids 2003;22:653-8.
51. Gmeiner WH, Salsbury F Jr, Olsen CM, Marky LA. The stability of a model substrate for topoisomerase 1-mediated DNA religation
depends on the presence of mismatched base pairs. J Nucleic Acids 2011;2011:631372.
52. Jennings-Gee J, Pardee TS, Gmeiner WH. Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10]
anti-leukemic activity. Exp Hematol 2013;41:180-8.e4.
53. Gmeiner WH, Gearhart PJ, Pommier Y, Nakamura J. F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a
unique mechanism for thymineless death. Future Oncol 2016;12:2183-8.
54. Das BB, Huang SY, Murai J, Rehman I, Ame JC, et al. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage.
Nucleic Acids Res 2014;42:4435-49.
55. Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by
FdUMP[10] results in high efficacy against AML and low toxicity. Blood 2012;119:3561-70.
56. Gmeiner WH, Willingham MC, Bourland JD, Hatcher HC, Smith TL, et al. F10 inhibits growth of PC3 xenografts and enhances the
effects of radiation therapy. J Clin Oncol Res 2014;2:pii:1028.
57. Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, et al. Selective anti-tumor activity of the novel fluoropyrimidine
polymer F10 towards G48a orthotopic GBM tumors. J Neurooncol 2014;116:447-54.
58. Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, et al. A phase I clinical trial of the Poly(ADP-ribose)
polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors. Clin Cancer Res 2018;24:744-52.
59. Murai J, Thomas A, Miettinen M, Pommier Y. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting
anti-cancer therapies. Pharmacol Ther 2019;201:94-102.